FDA picks Wave's DMD program for innovative trial pilot

Wave Life Sciences Ltd. (NASDAQ:WVE) said FDA has selected a Phase II/III trial of its Duchenne muscular dystrophy candidate suvodirsen (WVE-210201) for the agency's

Read the full 241 word article

User Sign In